Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Abroad (travel likely)RecruitingPHASE3
Conditions
Acute Myeloid Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
US-Cincinnati OH-CINCY, Cincinnati, Ohio, United States
Contact: Study coordinator (E. Curran)DE-Ulm-UNIKLINKULM, Ulm, Germany
Contact: Study coordinator (H. Döhner)NL-Breda-AMPHIA, Breda, Netherlands
Contact: Study coordinator (R. Fiets)NL-Eindhoven-MAXIMAMC, Eindhoven, Netherlands
Contact: Study coordinator (L. Tick)NL-Leeuwarden-FRISIUSMC, Leeuwarden, Netherlands
Contact: Study coordinator (B. Franken)NL-Nieuwegein-ANTONIUS, Nieuwegein, Netherlands
Contact: Study coordinator (M. Söhne)NL-Rotterdam-ERASMUCMC, Rotterdam, Netherlands
Contact: Study coordinator (M.H.G. Raaijmakers)NL-Den Haag-HAGA, The Hague, Netherlands
Contact: Study coordinator (D. Lammeren, van-Venema)
Study leads
M.H.G.P. Raaijmakers
Principal Investigator
Erasmus Medical Center